Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study

• Status: Unknown status
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Double - Blind, Randomized, single centered study. The purpose of this study is to assess the feasibility of minocycline vs. placebo, added to atypical antipsychotic medications, for positive symptoms in adults suffering from schizophrenia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shalvata Mental Health Center
• Treatments: Minocycline

Criteria

Inclusion Criteria:

• Men and women 20-65 years of age.

• Primary DSM-IV diagnosis of Schizophrenia based on SCID for schizophrenia and confirmed by two senior psychiatrists.

• Patients who scored "moderate" (4) or higher on at least three of seven positive items in PANSS

• Initiated on treatment with atypical anti-psychotic medication.

• Capable and willing to provide informed consent

• Able to adhere to the treatment schedule

• Able to read, hear, write and speak the local language.

• Has signed a written informed consent to participate in the study

Exclusion Criteria:

• Patients with acute, unstable, significant, or untreated medical illness besides schizophrenia including alcohol and drug dependence, or depression.

• Current suicidal ideation or history of a suicide attempt in the past 3 years

• Known or suspected pregnancy or women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse. or women who are breastfeeding

• Subjects who were taking a known contraindication to minocycline treatment.

• Subjects who had received treatment with minocycline or β-lactam antibiotics in the preceding half year before study entry.

• Subjects who were under compulsory hospitalization.